Vaxcyte Stock Performance

PCVX Stock  USD 75.23  0.86  1.16%   
The entity has a beta of 1.2, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vaxcyte will likely underperform. At this point, Vaxcyte has a negative expected return of -0.17%. Please make sure to validate Vaxcyte's potential upside and day median price , to decide if Vaxcyte performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Vaxcyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more

Actual Historical Performance (%)

One Day Return
1.14
Five Day Return
7.46
Year To Date Return
(9.70)
Ten Year Return
187.65
All Time Return
187.65
1
Acquisition by Elvia Cowan of 7716 shares of Vaxcyte at 25.92 subject to Rule 16b-3
12/16/2024
2
Disposition of 280 shares by Guggenhime Andrew of Vaxcyte at 90.241 subject to Rule 16b-3
12/18/2024
3
Disposition of 8000 shares by Wassil Jim of Vaxcyte at 2.42 subject to Rule 16b-3
01/02/2025
4
Disposition of 125 shares by Eydelman Mikhail of Vaxcyte at 86.52 subject to Rule 16b-3
01/06/2025
5
Acquisition by Eydelman Mikhail of 5000 shares of Vaxcyte at 21.41 subject to Rule 16b-3
01/07/2025
6
Disposition of 683 shares by Guggenhime Andrew of Vaxcyte at 87.7 subject to Rule 16b-3
01/21/2025
7
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
02/12/2025
8
How Has Vaxcyte Stock Performed Amid Market Fluctuations
02/25/2025
9
Q4 2024 Vaxcyte Inc Earnings Call Transcript
02/26/2025
10
Disposition of 2013 shares by Pickering Grant of Vaxcyte at 73.02 subject to Rule 16b-3
02/28/2025
11
Vaxcyte, Inc. Among the Cash-Rich Mid Cap Stocks to Buy Now
03/03/2025
12
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
03/04/2025
13
Insider Selling Vaxcyte, Inc. COO Sells 8,000 Shares of Stock
03/05/2025
14
Disposition of 2621 shares by Eydelman Mikhail of Vaxcyte at 70.388 subject to Rule 16b-3
03/07/2025
Begin Period Cash Flow398.6 M
  

Vaxcyte Relative Risk vs. Return Landscape

If you would invest  8,575  in Vaxcyte on December 18, 2024 and sell it today you would lose (1,052) from holding Vaxcyte or give up 12.27% of portfolio value over 90 days. Vaxcyte is currently does not generate positive expected returns and assumes 3.2393% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Vaxcyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Vaxcyte is expected to under-perform the market. In addition to that, the company is 3.79 times more volatile than its market benchmark. It trades about -0.05 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.02 per unit of volatility.

Vaxcyte Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaxcyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vaxcyte, and traders can use it to determine the average amount a Vaxcyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0528

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsPCVX

Estimated Market Risk

 3.24
  actual daily
28
72% of assets are more volatile

Expected Return

 -0.17
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.05
  actual daily
0
Most of other assets perform better
Based on monthly moving average Vaxcyte is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vaxcyte by adding Vaxcyte to a well-diversified portfolio.

Vaxcyte Fundamentals Growth

Vaxcyte Stock prices reflect investors' perceptions of the future prospects and financial health of Vaxcyte, and Vaxcyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaxcyte Stock performance.

About Vaxcyte Performance

Evaluating Vaxcyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Vaxcyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vaxcyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand(45.64)(47.93)
Return On Tangible Assets(0.13)(0.14)
Return On Capital Employed(0.17)(0.18)
Return On Assets(0.13)(0.14)
Return On Equity(0.14)(0.15)

Things to note about Vaxcyte performance evaluation

Checking the ongoing alerts about Vaxcyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vaxcyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Vaxcyte generated a negative expected return over the last 90 days
Vaxcyte has high historical volatility and very poor performance
Net Loss for the year was (463.93 M) with loss before overhead, payroll, taxes, and interest of (75 M).
Vaxcyte currently holds about 354.5 M in cash with (452.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.98.
Vaxcyte has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Evaluating Vaxcyte's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Vaxcyte's stock performance include:
  • Analyzing Vaxcyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaxcyte's stock is overvalued or undervalued compared to its peers.
  • Examining Vaxcyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Vaxcyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaxcyte's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Vaxcyte's stock. These opinions can provide insight into Vaxcyte's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Vaxcyte's stock performance is not an exact science, and many factors can impact Vaxcyte's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.